Myriad And Lumea Partner To Streamline Cancer Testing With Digital Pathology

Myriad Genetics Inc., a pioneer in genetic and genomic tumor testing, has teamed up with Lumea Inc., a leader in digital pathology solutions, to unite the Prolaris Prostate Cancer Test and MyRisk Hereditary Cancer Test with Lumea’s digital pathology platform BxLink™. 

“Clinicians need ready access to molecular diagnostic tools at the point of care to improve cancer outcomes. Prolaris, included in the recent NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer (NCCN Guidelines®), quantifies prostate cancer aggressiveness to guide treatment decisions at cancer diagnosis. At the same time, MyRisk evaluates 48 genes associated with hereditary cancer risk to guide treatments and identify risks to family members. This collaboration with Lumea ensures precision-based insights are delivered in a timely fashion when they’re needed most to empower patients and providers to make informed decisions,” said George Daneker, Jr., MD, President and Chief Clinical Officer, Oncology, Myriad Genetics.

The collaboration through enhanced integration allows healthcare providers to send electronic Prolaris and MyRisk test orders through BxLink, where results are delivered directly to the system’s easy-to-use interface. The integration replaces manual processing to minimize errors and plans to deliver molecular testing outcomes to clinicians through a maximum nine-day post-specimen-collection period.

Jim Pack, CEO of Lumea, stated, “This integration simplifies workflows for physicians. With fewer clicks and reduced data entry, clinicians can seamlessly order Myriad’s advanced tests, access actionable results within the platform they trust, and deliver personalized care. These insights can unlock advanced treatment options, targeted therapies, and clinical trials, driving improved patient outcomes.”